With Focus on CGRP, Development of New Generation of Preventive Treatments for Migraines Heating Up

In the development of preventive drugs for migraines, there is growing evidence of the preventive efficacy of using monoclonal antibodies to target the calcitonin gene-related peptide (CGRP) and its receptors. Clinical trials of next-generation preventive drugs such as erenumab (Amgen)...read more